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Background
A useful biomarker is an index that assists in the diagnosis of disease or the determination of disease severity. Diagnostic markers are important at preclinical or initial stages, while surrogate markers are important after the diagnosis. Biomarkers play an important role when novel treatments are discovered and clinical trials are performed.
Although there are various types of biomarkers such as molecular markers and imaging markers, an appropriate maker for neurodegenerative disease has not been identified. Thus, we use clinical evaluation scales. However, it is important to identify an appropriate biomarker in order to evaluate the efficiency of a given clinical trial.
Here, we performed gait analyses in patients with pure cerebellar type spinocerebellar degeneration (SCD) and assessed whether the obtained data could be used as a neurophysiological biomarker for cerebellar ataxia.
Here we performed gait analysis in patients with pure cerebellar type spinocerebellar degeneration (SCD) and assessed whether the obtained data could be used as a neurophysiological biomarker for cerebellar ataxia. 5 
Subjects and Methods

Subjects
From June 1, 2013 to August 31, 2014, we analyzed 25 SCD patients that included 16 patients with spinocerebellar ataxia (SCA 6), 2 patients with SCA31, 3 patients with dominant-inherited cerebellar cortical atrophy (DCCA), and 4 patients with cortical cerebellar atrophy (CCA). These SCD patients included 11 males and 14 females with an average age of 62.4±12.0 years (range, 24～83 years). We also analyzed 25 patients with Parkinson's disease (PD) as a disease control (13 male and 12 female; average age, 63.3±9.0 years; range 38-80 years) and 25 healthy control subjects (12 male and 13 female; average age, 57.6±17.1 years; range 32-84 years). The mean age and male-female ratio of the PD group and healthy control group were not significantly different from those of the SCD group .
We evaluated the clinical severity of each patient in the SCD group using the Scale for the Assessment and Rating of Ataxia (SARA) [1, 2] and the Berg Balance Scale (BBS) [3, 4] . The mean SARA of the SCD group was 13.26±4.43, while the mean Unified Parkinson's Disease Rating Scale (UPDRS) part III was 18.48±8.4760. 6 This study was approved by the ethics panels of Hokkaido University Hospital and Kushiro Rosai Hospital. (Fig. 1) Acceleration signals were measured during 6 min walking and 1 min standing tasks by two sets of triaxial accelerometers (Mimamori-gait system, LSI Medience; size, 7.5 cm × 5 cm × 2 cm; weight, 95 g) that were secured with a fixation vest to the middle of the subject's lower and upper back.
Methods
When in the standing position, the subjects were evaluated with their eyes open for 1 min and then their eyes closed for another 1 min. An assistant remained beside the subjects in order to prevent falls, however, no falls occurred. The subjects were evaluated while they shuttle-walked a 30 m straight line for 6 min (6-min walk test (6MWT) [5] ). Similar tasks were performed in the JASMITT study [6] and in other studies. When standing in the anatomical position, the orientation of the three acceleration axes, X, Y, and Z, were medial/lateral (ML), vertical (VT), and anterior/posterior (AP), respectively. Data were collected at a sampling frequency of 100 Hz and stored on a secure digital memory card inserted into the device for later analysis. 7 We extracted two gait parameters, the average and the coefficient of variation (CV) of the motion trajectory amplitude, from each acceleration component by the following methods:
1. The acceleration signal was integrated twice in the time domain and processed with high-pass filtering based on a moving-window average to generate motion trajectory, namely, relative displacement [7] .
2. The upper and lower envelopes of the trajectory signal (denoted as Y1 and Y2) were obtained by spline interpolation of its positive and negative peaks, respectively.
3. The amplitude time series was defined as (Y1 − Y2)/2, and divided into two parts: signals corresponding to straight walking and to turning around the cone. 4 . The average and CV of the amplitude time series were calculated separately for each part, which yielded the desired gait parameters.
To quantify body motion during standing, we examined parameters as follows:
1. The three acceleration components ax(t), ay(t), and az(t) were smoothed by a moving-window average with a window size of 5.6 s to generate three 8 baseline signals: Bx(t), By(t), and Bz(t). 
Statistical analysis
We used Student's t-test for inter-group comparison and Pearson's correlation coefficients for disease severity and each parameter analysis.
The JMPⓇ Pro 11.2.0 software program (SAS Institute Inc., Cary, NC, USA) was used for statistical analyses. We considered the results significant if p<0.05. The test of significance was adjusted for multiple testing using a Bonferroni step-down (Holm) correction.
Results
We compared each parameter of SCD patients to that of PD and healthy control subjects in Table 1 . A number of parameters of SCD Table 2 . A number of parameters showed a high correlation with BBS and SARA. The average amplitude and CV of straight gait showed a higher correlation than these parameters in standing and turning. In particular, the average amplitude of ML (upper back) and CV of VT (upper back) correlated most significantly with severity (Fig. 2) . In addition, these parameters correlated significantly with the SARA gait item (Supplemental Table 1 ).
We compared the average amplitude of ML (upper back) and CV of VT (upper back) of SCD patients with those of PD patients as the disease control.
The average amplitude of ML (upper back) of SCD patients was significantly larger than that of PD patients (Fig. 3) . Compared with the gait control of healthy control subjects, correlation with severity, and disease specificity, our results suggest that a physiological biomarker for cerebellar ataxia may be the average amplitude of ML (upper back) during straight gait.
We compared the correlation of each gait parameter with severity between that observed in the first 3 minutes and to that of the last 3 minutes (Supplemental Table 2 ). Each coefficient of correlation of the first and last 3 minutes was applied to a Brand-Altman plot, which demonstrated an intraclass correlation coefficient of 0.976, indicating that the results were not significantly different.
Discussion
Few studies have conducted quantitative analysis of gait disability in ataxic patients. Previously, we reported that SARA did not correlate with the total length traveled or the root mean square area of body sway as measured 11 by body stabilometry [8] . Some reports of gait analysis in PD patients have evaluated acceleration, but not amplitude or CV [9] .
Menz et al. reported that the magnitude of pelvis accelerations increased, while head accelerations were not affected by the walking surface when walking on an irregular surface [10] . In the present study, when we compared each parameter of the healthy control group by upper and lower back, the CV of ML and VT were lower in the upper back, while the CV of AP was lower in the lower back. Therefore, we chose the upper back of ML and VT, and the lower back of AP as evaluation positions.
We measured both mean amplitude and CV. The severity of cerebellar ataxia correlated strongest with the average amplitude of ML of straight gait in our study. The CV may indicate the control of gait. Thus, we selected the site with more control in healthy control subjects according to the CV data.
Our results suggest that the parameter of gait analysis may be a biomarker for cerebellar ataxia. We used clinical evaluation scales of cerebellar ataxia to determine the effect of the intervention trial. However, we need a greater number of objective patients in order to detect the effect of intervention using a category characteristics scale rather than a metric 12 variable scale [11] .
A previous study showed that 250 patients per group were required to detect a 50% reduction of disease progression within 1 year using SARA [11] .
We used the Unified Multiple System Atrophy Rating Scale (UMSARS), a clinical evaluation scale of cerebellar ataxia and multiple system atrophy (MSA). Sample size estimation showed that an interventional trial with 258 patients would be able to detect a 30% effect size in 1-year UMSARS motor examination decline rates at 80% power [12] .
A previous study indicated that fewer patients were required for the 9-hole peg test (9HPG) [11] . 9HPG is a metric variable of the amount of time required to perform the task. This suggests that a novel biomarker as a metric variable is needed to achieve an interventional study with fewer patients.
Another problem in the use of an evaluation scale of cerebellar ataxia is the lack of consideration of differences in pathogenesis or gene mutations.
The cerebellum plays a role as a comparator, which gains feed-forward control by reserving short-term memory in the cerebellar cortex and long-term memory in the cerebellar nucleus by afferent feed-back from 13 effector organs. However, we evaluate cerebellar cortex disordered disease, cerebellar nucleus disordered disease, and feed-back pathway disordered disease using the same evaluation scale. SARA is a scale constructed to assess various types of SCD [1] . Study of the natural course of SCD using SARA indicates that the type of SCD or the different repeat number results in a different deterioration rate [13] . Therefore, a clinical evaluation scale that considers the pathological findings or clinical symptoms of each disease is needed in interventional studies. In Friedreich's ataxia, there has been a successful interventional study of alpha-tocopherol using the specific scale that reflects its clinical symptoms, the Friedreich's Ataxia Rating Scale [14] .
However, it is difficult to produce each evaluation scale and carry out an interventional study for each disease because of the number of patients required. Since ataxic gait is a common early symptom of SCD, quantitative analysis of gait abnormality is most essential for the early intervention.
In the present study, gait distance also correlated significantly with SARA (data not shown). However, not every medical institution has sufficient space to perform the 6MWT, which is advantageous for CV and mean amplitude. Moreover, according to the comparison between the first 14 and last 3 minutes of gait, which were not significantly different, we may be able to shorten the gait minutes. Further study is needed to assess whether gait analysis over a short distance can be used as a biomarker for SCD.
While we have not established a quantitative evaluation for SCD, our gait analysis is more quantitative and concise than previous evaluation scales, SARA and BBS, which are bound to symptoms. It is unclear whether SARA is the best scale for ataxia, but, since there is no alternative, we assessed the coefficient correlation to SARA. Follow up study is needed to assess SARA and gait analysis to determine the deterioration rate and to calculate the sample size.
The establishment of a quantitative evaluation by gait analysis is important to determine the deterioration rate and to estimate the effect size in order to construct a plan of interventional trial with less patients and more significant results.
Conclusion
Our results suggest that gait analysis is a quantitative and concise evaluation scale for the severity of cerebellar ataxia. 
